|
RegeneRx Receives Notice of Allowance From U.S. Patent Office for New Ophthalmic Indications
RegeneRx Biopharmaceuticals announced it has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure.
BusinessWire |
Register Now
Archives